Second malignant neoplasms within 5 years from first primary diagnosis in pediatric oncology patients in Canada: a population-based retrospective cohort study.

Canada early second malignant neoplasm (early SMN) oncology pediatrics risk factors surveillance

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2024
Historique:
received: 25 01 2024
accepted: 11 03 2024
medline: 12 4 2024
pubmed: 12 4 2024
entrez: 12 4 2024
Statut: epublish

Résumé

From the advancement of treatment of pediatric cancer diagnosis, the five-year survival rate has increased significantly. However, the adverse consequence of improved survival rate is the second malignant neoplasm. Although previous studies provided information on the incidence and risk of SMN in long term survivors of childhood cancer, there is still scarce information known for short term (< 5 years) prognosis. This study aims to assess the incidence, characteristics, management, and outcome of children who develop SMN malignancies within 5 years of diagnosis of their initial cancer. This is a retrospective cohort study of early Second Malignant Neoplasms (SMN) in pediatric oncology patients. The Cancer in Young People - Canada (CYP-C) national pediatric cancer registry was used and reviewed pediatric patients diagnosed with their first cancer from 2000-2015. A total of 20,272 pediatric patients with a diagnosis of a first malignancy were analyzed. Of them, 0.7% were diagnosed with a SMN within the first 5 years following their first cancer diagnosis. Development of a SMN impacted survival, shown by an inferior survival rate in the SMN cohort (79.1%) after three years compared to that of the non-SMN cohort (89.7%). Several possible risk factors have been identified in the study including the use of epipodophyllotoxins, exposure to radiation, and hematopoietic stem cell 169 transplant. This is the first national study assessing the incidence, 170 characteristics, risk factors and outcome of early SMN in Canadian children 171 from age 0-15 from 2000-2015.

Identifiants

pubmed: 38606094
doi: 10.3389/fonc.2024.1376652
pmc: PMC11006957
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1376652

Informations de copyright

Copyright © 2024 Ricci, Subburaj, Lim, Shukla, Kaur, Xie, Laverty, Zakaria, Pole, Pelland-Marcotte, Barber, Israels, Tran, Oberoi, Renzi, MacDonald, Sung and Kulkarni.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Christina Ricci (C)

Lifespan Chronic Disease and Conditions Division, Public Health Agency of Canada, Ottawa, ON, Canada.

Divya Subburaj (D)

Department of Pediatrics, Division of Hematology-Oncology, Izzak Walton Killam (IWK) Health Centre, Halifax, NS, Canada.

Kate Lim (K)

Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.

Neetu Shukla (N)

Lifespan Chronic Disease and Conditions Division, Public Health Agency of Canada, Ottawa, ON, Canada.

Jaskiran Kaur (J)

Surveillance Systems and Data Management Division, Public Health Agency of Canada, Ottawa, ON, Canada.

Lin Xie (L)

Lifespan Chronic Disease and Conditions Division, Public Health Agency of Canada, Ottawa, ON, Canada.

Meghan Laverty (M)

Lifespan Chronic Disease and Conditions Division, Public Health Agency of Canada, Ottawa, ON, Canada.

Dianne Zakaria (D)

Lifespan Chronic Disease and Conditions Division, Public Health Agency of Canada, Ottawa, ON, Canada.

Jason Pole (J)

Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Centre for Health Sciences Research, University of Queensland, Brisbane, QLD, Australia.

Marie-Claude Pelland-Marcotte (MC)

Division of Pediatric Hematology-Oncology, CHU de Québec-Centre Mère-Enfant Soleil, Quebec City, QC, Canada.
Research Centre of the CHU de Québec, Axe Reproduction, Santé de la Mère et de l'Enfant, Quebec City, QC, Canada.

Randy Barber (R)

C17 Research Network, C17 Council, Edmonton, AB, Canada.

Sara J Israels (SJ)

Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada.

Thai-Hoa Tran (TH)

Department of Pediatrics, Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montréal, QC, Canada.
Immune Diseases and Cancers Axis, CHU Sainte-Justine Research Center, Montréal, QC, Canada.

Sapna Oberoi (S)

Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada.
Department of Pediatric Hematology-Oncology, CancerCare Manitoba, Winnipeg, MB, Canada.

Samuele Renzi (S)

Division of Hematology Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Tamara MacDonald (T)

Department of Pharmacy, Izzak Walton Killam (IWK) Health, Halifax, NS, Canada.
Faculty of Health Professions, Dalhousie University, Halifax, NS, Canada.

Lillian Sung (L)

Division of Hematology Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada.

Ketan Kulkarni (K)

Department of Pediatrics, Division of Hematology-Oncology, Izzak Walton Killam (IWK) Health Centre, Halifax, NS, Canada.

Classifications MeSH